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Background: Serolimus-eluting stents (SES) reduce late repeat TLR, over to bare metal stents (BMS). However, SES have been implicated in 
late thrombotic events. The Genous bio-engineered R stent (Gs), by the recruitment of circulating endothelial progenitors, induce rapid stent 
endothelization and may reduce the occurrence of both TLR and late thrombotic events. We compared the 2-year efficacy of Gs vs SES vs BMS in 
patients who underwent coronary stenting due to stable or unstable coronary syndromes.
Methods: 345 pts who underwent Gs stenting were compared with 2 parallel groups of 690 pts each who underwent SES and BMS implantation 
respectively. The 2-year incidence of the composite of cardiac death, rehospitalization for non-fatal MI and TLR was the primary endpoint.
Results: There were not significant differences in baseline clinical and angiographic characteristics between Gs, SES and BMS pts. The 2-year 
incidence of the primary endpoint and its components are presented in the figure. A similar percentage of Gs and SES pts reached the primary 
end point (p=0.91). However BMS pts had higher rate of the primary end point than Gs (p=0.001) and SES (p=0.001) pts. Although, there was no 
any difference in the incidence of death (p=0.84) or MI (p=0.77) among the 3 groups, BMS pts had higher rate of TLR over Gs (p=0.001) and SES 
(p<0.001) pts.
Conclusions: Pts treated with Genous stent have a similar to BMS treated pts long term incidence of thrombotic coronary events and similar to 
SES treated pts long term incidence of TLR 
